Investing.com - AbbVie (NYSE:ABBV) reported on Friday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
AbbVie announced earnings per share of $2.34 on revenue of $10.43B. Analysts polled by Investing.com anticipated EPS of $2.2 on revenue of $9.93B.
AbbVie shares are up 8% from the beginning of the year , still down 5.17% from its 52 week high of $101.28 set on July 17. They are outperforming the S&P 500 which is up 0.48% from the start of the year.
AbbVie shares gained 2.25% in pre-market trade following the report.
AbbVie follows other major Healthcare sector earnings this month
AbbVie's report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.69B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in ABBV right now?
With ABBV making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ABBV alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ABBV, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ABBV poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now